CD33-SPECIFIC CHIMERIC ANTIGENIC RECEPTORS FOR CANCER IMMUNOTHERAPY Russian patent published in 2019 - IPC C07K16/28 A61K39/395 A61P35/02 

FIELD: biotechnologies.

SUBSTANCE: invention relates to the biotechnology. Disclosed is a CD33-specific chimeric antigenic receptor (CAR) having a polypeptide structure selected from V1, V3 and V5, which are illustrated in figure 2. Said structure comprises: (a) an extracellular ligand-binding domain containing VH and VL from a monoclonal antibody to CD33, (b) a hinge selected from a FcRIIIα hinge, CD8α hinge and IgG1 hinge, (c) transmembrane CD8α domain and (d) a cytoplasmic domain comprising a CD3-domain signal domain and a costimulatory domain of 4-1BB. Disclosed is a method for haematological cancer cell destruction involving contacting said haematological cancer cell with a constructed immune cell in an amount effective for destroying said cancer cell. Described also is a constructed immune cell expressing CD33-specific CAR cell surface membrane.

EFFECT: constructed immune cells endowed with said CAR are most suitable for treating lymphomas and leukaemias.

41 cl, 8 dwg, 11 tbl, 3 ex